Lyda Espitia-Pérez

Prof. Dr. Lyda Espitia-Pérez

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Verified
Journal Article
Closed access
LELyda Espitia-Pérez
Lyda Espitia-Pérez
MSMilton Quintana Sosa
Milton Quintana Sosa
SSShirley Salcedo-Arteaga
Shirley Salcedo-Arteaga
GLGrethel León-Mejía
Grethel León-Mejía
LHLuz Stella Hoyos-Giraldo
Luz Stella Hoyos-Giraldo
JHJoão Antonio Pegas Henriques
João Antonio Pegas Henriques

1 September 2018 in Chemosphere
Verified
Journal Article
Closed access
LELyda Espitia-Pérez
Lyda Espitia-Pérez
MPMarcia Arteaga - Pertuz
Marcia Arteaga - Pertuz
JSJosé Salvador Soto
José Salvador Soto
Pedro Juan Espitia-PérezPedro Juan Espitia-Pérez
Pedro Juan Espitia-Pérez
SSShirley Salcedo-Arteaga
Shirley Salcedo-Arteaga
JHJoão A.P. Henriques
João A.P. Henriques

1 February 2021 in Chemosphere
Verified
Journal Article
Closed access
CPClaudia Milena Galeano Paez
Claudia Milena Galeano Paez
Pedro Juan Espitia-PérezPedro Juan Espitia-Pérez
Pedro Juan Espitia-Pérez
LJLuisa Jimenez-Vidal
Luisa Jimenez-Vidal
KPKarina Susana Pastor
Karina Susana Pastor
SSShirley Salcedo
Shirley Salcedo
LELyda Espitia-Pérez
Lyda Espitia-Pérez

1 December 2018 in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Verified
Journal Article
Closed access
LELyda Espitia-Pérez
Lyda Espitia-Pérez
Juliana Da silvaJuliana Da silva
Juliana Da silva
HBHugo Brango
Hugo Brango
Pedro Juan Espitia-PérezPedro Juan Espitia-Pérez
Pedro Juan Espitia-Pérez
KPKarina Pastor-Sierra
Karina Pastor-Sierra
JHJoão Antonio Pegas Henriques
João Antonio Pegas Henriques

Verified
Journal Article
Open access
PDF file
Pedro Juan Espitia-PérezPedro Juan Espitia-Pérez
Pedro Juan Espitia-Pérez
LELyda Espitia-Pérez
Lyda Espitia-Pérez
MNMario Negrette
Mario Negrette
Prostate cancer (PCa) therapy faces challenges due to tumor heterogeneity, plasticity, and progression. Metabolic reprogramming, a dynamic process, has emerged as a key focus in PCa treatment. However, conventional therapies targeting cancer-specific metabolic pathways or employing chemosensitizers are often limited by compensatory mechanisms and metabolic complexity. This review highlights the roles of transcription factors, including AR, p53, c-Myc, HIF-1, Nrf2, and PPARγ, in regulating PCa metabolism by influencing signaling pathways, enzymes, and gene expression. Multi-target compounds, particularly natural products, show potential for disrupting multiple metabolic enzymes, opening up new research possibilities. Notable examples include β-elemene, juglone, tannic acid, and withaferin A, which target critical metabolic processes through enzyme inhibition, transcription factor modulation, epigenetic changes, and protein interaction disruption. Naturally derived metabolites can elicit transversal responses in diverse metabolic pathways, particularly in p53 and MYC transcription factors. Additionally, compounds such as pentacyclic terpenoids (ursolic acid with ursane skeleton), sulforaphane, and isothiocyanate-related moieties may induce metabolic and epigenetic changes through S-adenosyl methionine (SAM) and acetyl-CoA modulation, potentially affecting new areas of research through metabolic processes. We propose a cooperative crosstalk between metabolic reprogramming and transcription factors/epigenetic modulation in PCa. This approach holds potential for expanding PCa therapeutics and opening new avenues for research.

19 December 2019 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
LJLuisa Jiménez-Vidal
Luisa Jiménez-Vidal
Pedro Juan Espitia-PérezPedro Juan Espitia-Pérez
Pedro Juan Espitia-Pérez
JTJosé Torres-Ávila
José Torres-Ávila
DRDina Ricardo-Caldera
Dina Ricardo-Caldera
SSShirley Salcedo-Arteaga
Shirley Salcedo-Arteaga
LELyda Espitia-Pérez
Lyda Espitia-Pérez
Background: Nickel and nickel-containing compounds (NCC) are known human carcinogens. However, the precise molecular mechanisms of nickel-induced malignant transformation remain unknown. Proposed mechanisms suggest that nickel and NCC may participate in the dual activation/inactivation of enzymatic pathways involved in cell defenses against oxidative damage, where Nuclear factor-erythroid 2 related factor 2 (Nrf2) plays a central role.Methods: For assessing the potential role of proteins involved in the Nrf2-mediated response to nickel and NCC exposure, we designed an interactome network using the STITCH search engine version 5.0 and the STRING software 10.0. The major NCC-protein interactome (NCPI) generated was analyzed using the MCODE plugin, version 1.5.1 for the detection of interaction modules or subnetworks. Main centralities of the NCPI were determined with the CentiScape 2.2 plugin of Cytoscape 3.4.0 and main biological processes associated with each cluster were assessed using the BiNGO plugin of Cytoscape 3.4.0.Results: Water-soluble NiSO4and insoluble Ni3S2were the most connected to proteins involved in the NCPI network. Nfr2 was detected as one of the most relevant proteins in the network, participating in several multifunctional protein complexes in clusters 1, 2, 3 and 5. Ontological analysis of cluster 3 revealed several processes related to unfolded protein response (UPR) and response to endoplasmic reticulum (ER) stress.Conclusions: Cellular response to NCC exposure was very comparable, particularly concerning oxidative stress response, inflammation, cell cycle/proliferation, and apoptosis. In this cellular response, Nfr2 was highly centralized and participated in several multifunctional protein complexes, including several related to ER-stress. These results add evidence on the possible Ni2+induced – ER stress mainly associated with insoluble NCC. In this scenario, we also show how protein degradation mediated by ubiquitination seems to play key roles in cellular responses to Ni.